Stephen Yoo,Rickey Robert Reinhardt,Sherri Van Everen,Karen Fran Kozarsky,Curran Matthew Simpson,Zhuchun Wu,Peter Anthony Campochiaro,Jikui Shen,Kun Ding
申请号：
US16645877
公开号：
US20200277364A1
申请日:
2018.09.26
申请国别(地区):
US
年份:
2020
代理人:
摘要：
Compositions and methods are described for the delivery of a fully human post-translationally modified (HuPTM) monoclonal antibody (“mAb”) or the antigen-binding fragment of a mAb against human vascular endothelial growth factor (“hVEGF”)—；such as, e.g., a fully human-glycosylated (HuGly) anti-hVEGF antigen-binding fragment—；to the retina/vitreal humour in the eye(s) of human subjects diagnosed with ocular diseases caused by increased neovascularization, for example, neovascular age-related macular degeneration (“nAMD”), also known as “wet” age-related macular degeneration (“WAMD”), age-related macular degeneration (“AMD”), and diabetic retinopathy.
